Navigation Links
Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
Date:5/6/2008

ng surgery, Cethrin is delivered by a single application to the injured region of the spinal cord. Cethrin has been designated as an Orphan Drug by the FDA.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's focus is reflected in several important initiatives. Cethrin, a recombinant- protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technol
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Decision Resources ... specialties (medical oncology, hematology-oncology, rheumatology, gastroenterology, endocrinology and ... trials that a biosimilar has been assessed in ... product they choose to prescribe. ... report entitled Acceptance of Biosimilars Across ...
(Date:8/27/2014)... , Aug. 27, 2014   Los Angeles orthodontics ... AcceleDent® Aura to patients who want to make their ... available at the OrthoSpaceship, all patients have a powerful ... This system can be used by most patients with ... of progress by using the AcceleDent® Aura system for ...
(Date:8/27/2014)... Decision Resources Group finds that the intense ... health system and hospital sector in recent ... Methodist Le Bonheur Healthcare and Baptist Memorial Health Care ... care. In addition, a national contract recently signed between ... enrollment in the Memphis market, ...
Breaking Medicine Technology:Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Memphis-area Health Systems Turn Attention to Clinical Integration 2
... 15, 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiac ... quarter ended June 30, 2011. More details on the financial ... 10-Q, filed today with the Securities and Exchange Commission. ... a top 5 global pharmaceutical company for two Phase I ...
... 15, 2011 For the first time, the ... guidance clarifying how benefit-risk determinations are made during ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Released today, ... the regulatory pathway for high-risk medical devices. The ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8FDA Proposes Guidelines That Clarify Benefit-Risk Determinations for Medical Devices 2
(Date:8/27/2014)... Home Care Assistance of Scottsdale , ... proud to announce the next installment in its renowned ... Dr. Suzanne Steinbaum, attending cardiologist and Director of Women’s ... City, National Spokesperson for the American Heart Association’s Go ... issues surrounding women and heart disease, what heart disease ...
(Date:8/27/2014)... of clinical trial participation in the largest ongoing observational ... are not representative of the larger patient base, according ... Dr. Jay Udell. The study authors call into question ... population, and suggest the use of broader enrollment criteria ... "We know that clinical trials can be tremendously expensive ...
(Date:8/27/2014)... tested an advanced statistical model to evaluate the ... as published yesterday in Human Genetics . ... in current analyses. Complex diseases like cancer usually ... factors. When many such combinations are studied, identifying ... combinations among affected individuals becomes difficult. In this ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Cash House ... impact on the overall upkeep of the shelter including new ... importantly helping to change the lives of each youth who ... 35 bed emergency shelter for youth ages 16-25. Not only ... many programs and resources for the youth who come through ...
(Date:8/27/2014)... Lighthouse Payment Services Inc ., a leader ... exhibit its image-based lockbox services at the Independent Bankers ... in beautiful Lake Placid, New York from September 7th ... at the Lake Placid Convention Center and will feature ... addition to a variety of vendors exhibiting the latest ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Cash House a Major Supporter of Horizons for Youth 2Health News:Cash House a Major Supporter of Horizons for Youth 3
... (Carlsbad, CA) and its development partner, Logical Therapeutics, Inc. ... active comparator study of LT-NS001 (formerly MX-1094) vs naproxen, ... LT-NS001 is a novel, patented NCE prodrug of the ... developed to significantly reduce the GI safety risks, including ...
... 30-Year Finance Executive Veteran Adds Public Accounting, Executive ... Smith announced today that Dave Watkins has been ... responsible for overseeing all Company financial functions, including ... forecasts and tax planning. H. D. Smith ...
... Time Spent Caring for Parents with Alzheimer,s in Heartfelt New ... memoirs, "36 Days Apart: A memoir of a daughter, her ... Life, Love and Death" ( published by AuthorHouse ... of her mother and father, both of whom were diagnosed ...
... - Discovery Health,s Seventh Annual Programming Event Presents Baby ... 14, through Friday, June 19 - SILVER SPRING, Md., ... the third week of June to deliver the network,s ... pregnancies, to surprise deliveries, to expectant mothers big and ...
... prebiotics market is diversifying and expanding in ... and beverage industry, with several exciting developments ... and the expansion of prebiotic ingredients into ... and meat products.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )New prebiotic ...
... of 14 Hydroxycut products, consumers who have suffered injuries from using ... products liability attorney to determine if he/she is eligible for compensation. ... , ... San Diego, CA (PRWEB) May 26, 2009 ...
Cached Medicine News:Health News:Medinox Announces Clinical Results of Naproxen Prodrug 2Health News:H. D. Smith Appoints Dave Watkins Chief Financial Officer 2Health News:New Memoir Details Effects of Alzheimer's on Family 2Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 2Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 3Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 4Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 2Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 3Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 4Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 5Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 6Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 7Health News:LawInfo Provides Access to Qualified Hydroxycut Litigation Attorneys Nationwide 2
... Series from Thermo delivers maximum ... your low-speed clinical applications. With ... system, user-friendly controls, and generous ... Series delivers solid performance for ...
... CL30 Series from Thermo delivers ... for your low-speed clinical applications. ... exchange system, user-friendly controls, and ... CL30 Series delivers solid performance ...
Chembio Diagnostic Systems, Inc.s SURE CHECK HIV 1 / 2, HIV 1/ 2 STAT-PAK and HIV 1/ 2 STAT-PAK Dipstick tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of anti...
When you use the optional REAL-Time Continuous Glucose Monitoring Kit with your insulin pump, you will have access to REAL-Time glucose readings, safety alarms, and glucose trend data around the cloc...
Medicine Products: